Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Acq. announced
Appointed director
BIOMARIN PHARMACEUTICAL INC (BMRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/27/2023 8-K Quarterly results
Docs: "BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business •VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 Billion"
08/03/2022 8-K Quarterly results
Docs: "BioMarin Announces Record Revenues in Second Quarter 2022&#59; Increases Full-year 2022 Top and Bottom-line Guidance •VOXZOGO™ $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter&#59; Total Revenues Grew 13% Year-Over-Year, Excluding Kuvan"
04/27/2022 8-K Quarterly results
Docs: "BioMarin Announces Record Revenues in First Quarter 2022"
02/23/2022 8-K Quarterly results
Docs: "BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates"
10/27/2021 8-K Quarterly results
Docs: "BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates"
07/28/2021 8-K Quarterly results
Docs: "BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates"
02/25/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million"
08/04/2020 8-K Quarterly results
04/29/2020 8-K Quarterly results
Docs: "BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million"
02/26/2020 8-K Quarterly results
10/23/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "BioMarin Announces Second Quarter 2019 Financial Results - Total Revenues of $387.8 million in the Quarter - Full-year 2019 Total BioMarin Revenue Guidance of Between $1.68 billion to $1.75 billion Reaffirmed - As of June 30, 2019, 551 U.S. Commercial Patients Receiving Treatment with Palynziq ® Financial Highlights Three Months Ended June 30, Six Months Ended June 30, 2019 2018 % Change 2019 2018 % Change Total Revenues $ 387.8 $ 372.8 4 % $ 788.5 $ 746.3 6 %"
04/25/2019 8-K Quarterly results
Docs: "BioMarin Announces First Quarter 2019 Financial Results - Total Revenues Top $400 million in the Quarter - Full-year 2019 Total BioMarin Revenue Guidance of Between $1.68 billion to $1.75 billion Reaffirmed"
02/21/2019 8-K Quarterly results
10/25/2018 8-K Quarterly results
Docs: "BioMarin Announces Third Quarter 2018 Results - First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion - 124 Commercial Patients Receiving Treatment with Palynziq in First Full Quarter since U.S. Approval"
04/25/2018 8-K Quarterly results
Docs: "BioMarin Announces First Quarter 2018 Financial Results - Total Revenues Top $373 million in the Quarter; GAAP Net Loss of $44 million; Non-GAAP Income of $21 million"
02/22/2018 8-K Quarterly results
Docs: "BioMarin Announces Fourth Quarter and Full Year 2017 Financial Results - Record Total Revenues of $1.3 Billion for Full Year 2017 Representing an 18% Increase Year over Year"
10/26/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
05/04/2017 8-K Form 8-K - Current report
02/23/2017 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
04/28/2016 8-K Form 8-K - Current report
02/25/2016 8-K Quarterly results
Docs: "BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results - Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year - Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line"
10/29/2015 8-K Quarterly results
Docs: "Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 % Change 2015 2014 % Change"
08/03/2015 8-K Quarterly results
Docs: "BioMarin Announces Second Quarter 2015 Financial Results and Company Update - In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y - First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of Achondroplasia Financial Highlights"
04/30/2015 8-K Quarterly results
Docs: "BioMarin Announces First Quarter 2015 Financial Results and Company Update - Vimizim Sales Top $50 million in First Quarter of 2015 and $127 million in First Four Quarters Since Launch - Full-year Vimizim Guidance Increased to $200 million to $220 million; Full-year Total Revenue Guidance increased to $850 million to $880 million - Rolling NDA Submission Completed for Drisapersen Financial Highlights"
02/25/2015 8-K Quarterly results
Docs: "BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results Total BioMarin Revenue Increased 37% to $751 million in 2014 Rolling Submission of NDA for Drisapersen Underway; Acquisition of Prosensa Complete Financial Highlights"
10/23/2014 8-K Quarterly results
Docs: "BioMarin Announces Third Quarter 2014 Financial Results - VIMIZIM ® Sales Top $25 million in Second Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased Financial Highlights"
07/30/2014 8-K Quarterly results
Docs: "BioMarin Announces Second Quarter 2014 Financial Results - VIMIZIM ® Sales Top $14 million in First Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased Financial Highlights"
05/01/2014 8-K Quarterly results
Docs: "BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM™ Launch Progress - Total BioMarin Revenue Grew 18.5% in 1Q14 - 50 Patients Receiving Commercial VIMIZIM as of April 30 - VIMIZM Approved in the U.S. and E.U; Commercial Launch Underway in both Regions - PEG PAL Pivotal Study to be Optimized; Data Expected in 4Q15 Financial Highlights"
02/27/2014 8-K Quarterly results
Docs: "BioMarin Announces Fourth Quarter and Full Year 2013 Financial Results Total Revenue Grows 9.5% in 2013 U.S. Commercial Launch of VIMIZIM™ Underway; Positive CHMP Opinion Received February 20 Financial Highlights"
10/24/2013 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy